Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating) released its earnings results on Monday. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.16, Briefing.com reports. The company had revenue of $20.30 million during the quarter, compared to analysts’ expectations of $15.55 million. Y-mAbs Therapeutics had a negative net margin of […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) – Investment analysts at Wedbush issued their FY2027 earnings per share (EPS) estimates for shares of Y-mAbs Therapeutics in a research report issued on Wednesday, May 10th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($0.42) per share for the year. Wedbush has a “Outperform” rating […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) has been assigned an average recommendation of “Hold” from the twelve ratings firms that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and four have assigned a buy recommendation to the company. The […]
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating) will be issuing its quarterly earnings data after the market closes on Monday, May 8th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link. Y-mAbs Therapeutics (NASDAQ:YMAB – Get […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totalling 2,500,000 shares, a growth of 26.9% from the March 15th total of 1,970,000 shares. Based on an average daily volume of 678,200 shares, the days-to-cover ratio is […]